In the U.S.
Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to deliver 8% to 10% growth over the prior year.
government's COVID-19 vaccine distribution; $0.85 to $1.05 related to the kitting, storage and distribution of ancillary supplies; $0.75 to $0.95 related to COVID-19 tests; and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range of $0.50 to $0.75; and approximately $0.49 from gains and losses associated with McKesson Ventures' equity investments, which are within our corporate segment.
For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accretion in the first half of fiscal 2023 related to the held-for-sale accounting based on the current estimated close date for the PHOENIX Group transaction.
